Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta

Journal of Bone and Mineral Research

Volumn 28, Issue 1, 2013, Pages 73-80

  Sinder, Benjamin P ^a,b   Eddy, Mary M ^a   Ominsky, Michael S ^c   Caird, Michelle S ^a   Marini, Joan C ^d   Kozloff, Kenneth M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c AMGEN INC   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

ANABOLIC THERAPY; BONE MASS; COLLAGEN; OSTEOGENESIS IMPERFECTA; SCLEROSTIN ANTIBODY

Indexed keywords

CYSTEINE; GLYCINE; OSTEOCALCIN; PROTEIN ANTIBODY; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE FRAGILITY; BONE LENGTH; BONE MASS; BONE STRENGTH; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFICACY; ENZYME ACTIVITY; FEMUR; MALE; MINERALIZATION; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOGENESIS IMPERFECTA; PROTEIN BLOOD LEVEL; TRABECULAR BONE;

ACID PHOSPHATASE; ANIMALS; ANTIBODIES; BIOLOGICAL MARKERS; BIOMECHANICS; BODY WEIGHT; CALCIFICATION, PHYSIOLOGIC; DISEASE MODELS, ANIMAL; FEMUR; FLUORESCEINS; GLYCOPROTEINS; ISOENZYMES; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NANOTECHNOLOGY; ORGAN SIZE; OSTEOCALCIN; OSTEOGENESIS; OSTEOGENESIS IMPERFECTA; X-RAY MICROTOMOGRAPHY;

EID: 84872844733     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1717     Document Type: Article

References (37)

1. Forlino A, Cabral WA, Barnes AM, Marini JC,. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011; 7: 540-57.
2. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C,. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004; 363: 1427-31.
3. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S,. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005; 20: 758-63.
4. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC,. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005; 20: 977-86.
5. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH,. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009; 24: 1282-9.
6. Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH,. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011; 96: 355-64.
7. Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D,. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008; 23: 1698-707.
8. Padhi D, Jang G, Stouch B, Fang L, Posvar E,. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19-26.
9. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J,. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB.J. 2005; 19: 1842-4.
10. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE,., Wu D,. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883-7.
11. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M,. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011; 286: 19489-500.
12. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C,. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578-88.
13. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C,. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25: 948-59.
14. Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC,. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an α1(I) G349C substitution. J Biol Chem. 1999; 274: 37923-31.
15. Kozloff KM, Carden A, Bergwitz C, Forlino A, Uveges TE, Morris MD, Marini JC, Goldstein SA,. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res. 2004; 19: 614-22.
16. Uveges TE, Collin-Osdoby P, Cabral WA, Ledgard F, Goldberg L, Bergwitz C, Forlino A, Osdoby P, Gronowicz GA, Marini JC,. Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res. 2008; 23: 1983-94.
17. Meganck JA, Kozloff KM, Thornton MM, Broski SM, Goldstein SA,. Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD. Bone. 2009; 45: 1104-16.
18. Otsu N,. A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern. 1979; 9: 62-6.
19. Hildebrand T, Rüegsegger P,. A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc. 1997; 185: 67-75.
20. Oliver WC, Pharr GM,. An improved technique for determining hardness and elastic modulus using load and displacement sensing indentation experiments. J Mater Res. 1992; 7: 1565.
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR,. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-5610.
22. Busa B, Miller LM, Rubin CT, Qin Y-X, Judex S,. Rapid establishment of chemical and mechanical properties during lamellar bone formation. Calcif Tissue Int. 2005; 77: 386-94.
23. Donnelly E, Boskey AL, Baker SP,. van der Meulen MCH. Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex. J Biomed Mater Res A. 2010; 92: 1048-56.
24. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB,. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30: 312-21.
25. Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM,. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res. 2003; 18: 237-43.
26. Papapoulos SE, Cremers SCLM,. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007; 356: 1075-6.
27. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H,. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res. 2004 Jun; 19 (6): 999-1005.
28. Li J, Mashiba T, Burr DB,. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int. 2001; 69: 281-6.
29. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB,. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000; 15: 613-20.
30. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB,. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001; 28: 524-31.
31. Allen MR, Reinwald S, Burr DB,. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int. 2008; 82: 354-60.
32. Davis MS, Kovacic BL, Marini JC, Shih AJ, Kozloff KM,. Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta. Bone. 2012; 50: 784-91.
33. Uveges TE, Kozloff KM, Ty JM, Ledgard F, Raggio CL, Gronowicz G, Goldstein SA, Marini JC,. Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res. 2009; 24: 849-59.
34. Forlino A, Kuznetsova NV, Marini JC, Leikin S,. Selective retention and degradation of molecules with a single mutant [alpha]1(I) chain in the Brtl IV mouse model of OI. Matrix Biol. 2007; 26: 604-14.
35. Reich A, Cabral W, Marini J,. Altered transcript pattern during osteoblast differentiation associated with improved bone phenotype in homozygous osteogenesis imperfecta Brtl mice. J Bone Miner Res. 2011; 26 (Suppl 1).
36. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK,. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum. 2011; 63: 2385-95.
37. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C,. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860-9.